Cardiovascular Systems Stock

Cardiovascular Systems Debt

Delisted

The Debt of Cardiovascular Systems (CSII) as of Aug 26, 2026 is 20.30 M USD. In the previous year, Debt was 20.60 M USD — a change of -1.45% (lower).

Debt

20.30 MUSD

YoY

-1.45%

Last updated:

In 2026, Cardiovascular Systems's total debt was 20.30 M USD, a -1.45% change from the 20.60 M USD total debt recorded in the previous year.

The Cardiovascular Systems Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt
Date
Debt
Jan 1, 2015
0.00 USD
Jan 1, 2016
0.00 USD
Jan 1, 2017
21.10 M USD
Jan 1, 2018
21.10 M USD
Jan 1, 2019
21.00 M USD
Jan 1, 2020
20.80 M USD
Jan 1, 2021
20.60 M USD
Jan 1, 2022
20.30 M USD
The Cardiovascular Systems Debt history
YEARDebtYoY
20.30 MUSD-1.45%
20.60 MUSD-0.98%
20.80 MUSD-0.95%
21.00 MUSD-0.47%
21.10 MUSD0.00%
21.10 MUSD
0.00USD
0.00USD-100.00%
2.40 MUSD
Access this data via the Eulerpool API

Cardiovascular Systems Stock analysis

What does Cardiovascular Systems do? Cardiovascular Systems Inc. (CSI) is a US medical technology company founded in 1989. The company is headquartered in St. Paul, Minnesota and employs approximately 1,000 employees worldwide. CSI develops, manufactures, and distributes innovative devices for the treatment of vascular diseases. The business model of CSI is based on the development and marketing of medical devices for minimally invasive treatment of vascular diseases. The company generates a significant portion of its revenues through the sale of its products to hospitals and specialized healthcare facilities. Additionally, CSI also offers training and educational programs for doctors and medical personnel to optimize the use of their devices. CSI operates in two main segments: peripheral arterial disease (PAD) and coronary heart disease (CHD). The PAD segment includes devices for the treatment of vascular diseases outside of the heart, such as peripheral arterial occlusive disease (PAOD). This includes the Diamondback-360® catheter and the Stealth 360® catheter, both used for plaque ablation in the arteries. The CHD segment focuses on the treatment of heart diseases such as coronary artery disease (CAD). This includes the Orbital Atherectomy System (OAS), a device that can reduce the use of stents in patients with more severe coronary artery narrowings. CSI's core product is the Diamondback-360® catheter, which was approved by the US Food and Drug Administration (FDA) in 2013. This device consists of a rotating catheter inserted into the artery to remove plaque causing vessel narrowing. The Diamondback-360 catheter is used for the treatment of PAD and has the potential to significantly improve patients' quality of life. Another important product from CSI is the Orbital Atherectomy System (OAS), used for the treatment of CAD. The OAS system is a rotating catheter that can remove plaque in the coronary arteries to improve blood flow. The use of OAS can potentially avoid costly and invasive procedures such as coronary angiography or bypass. In summary, Cardiovascular Systems Inc. is a leading company in the development and production of innovative devices for minimally invasive treatment of vascular diseases. The company specializes in two main segments, peripheral arterial disease and coronary heart disease. With products like the Diamondback-360 catheter and the Orbital Atherectomy System, CSI has established itself as a reliable provider of high-quality medical devices. Through training and educational programs, CSI also contributes to improving medical care and the development of treatment methods. Cardiovascular Systems is one of the most popular companies on Eulerpool.

Debt Details

Understanding Cardiovascular Systems's Debt Structure

Cardiovascular Systems's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Cardiovascular Systems's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Cardiovascular Systems’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Cardiovascular Systems’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Cardiovascular Systems stock

Debt of Cardiovascular Systems is 20.30 M USD in 2026.

Debt of Cardiovascular Systems changed from 20.60 M USD to 20.30 M USD, representing a -1.45% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Debt Cardiovascular Systems since 2006 – with annual values, charts, and detailed analysis.

Debt's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Debt's Cardiovascular Systems historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Cardiovascular Systems

All Key Metrics — Cardiovascular Systems